Meeting
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Authors
John Leonard
Weill Cornell Medical College, New York, NY
John Leonard , Pier Luigi Zinzani , Wojciech Jurczak , Mathias J. Rummel , Gilles A. Salles , Eva Kimby , Hendrik-Tobias Arkenau , Andrew John Davies , David Michael Johnson , Shelley Evans , Roger D. Dansey , Wayne R. Godfrey , Brad S. Kahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01732913
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8617)
DOI
10.1200/jco.2013.31.15_suppl.tps8617
Abstract #
TPS8617
Poster Bd #
58A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
First Author: Sven De Vos
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
First Author: Gilles A. Salles
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat